Printer Friendly

ANGEION CORPORATION ENTERS INTO AGREEMENT WITH SIEMENS PACESETTER, INC.

 MINNEAPOLIS, Feb. 4 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) and Siemens Pacesetter, Inc. have entered into an agreement which provides for the licensing, manufacture and marketing of implantable cardioverter defibrillator devices (ICBs) and laser catheter ablation products. Such devices are designed to treat tachyarrhythmias, a market estimated to exceed $1 billion in sales by the year 2000.
 Under terms of the agreement, Siemens Pacesetter, Inc. will acquire shares of convertible preferred stock in Angeion Corporation, as well as a convertible debenture. Specific terms were not disclosed. Siemens acquires exclusive OEM license of Angeion's defibrillator products and nonexclusive OEM license of Angeion's laser catheter cardiac ablation products. Angeion acquires nonexclusive license of Siemens' defibrillator patents.
 Angeion retains the rights to its patents and the right to manufacture and sell its devices under its own label. Angeion will remain an independent company with its stock continuing to trade on the over-the-counter market.
 Siemens Pacesetters is one of the largest manufacturers of cardiac pacing devices in the world. A leading developer and manufacturer of implantable cardiac rhythm management devices, Siemens has independent ICD development underway in its Sylmar and Solna, Sweden facilities.
 Minneapolis-based Angeion Corporation is exclusively focused on the development of three high technology products for treating arrhythmias (irregular heartbeats). Angeion is evaluating its laser catheter ablation system and mapping technology in human clinical trials. Angeion is also developing an automatic implantable defibrillator. An external temporary pacemaker is currently under regulatory review.
 -0- 2/4/93
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN)


CO: Angeion Corporation; Siemens Pacesetter, Inc. ST: Minnesota IN: MTC SU: JVN

KH -- MN012 -- 3041 02/04/93 13:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 4, 1993
Words:271
Previous Article:CARSON GOLD CORP. HAS REACHED AN AGREEMENT ON THE LA RAYA CONCESSION, KILOMETER 88 MINING DISTRICT, VENEZUELA
Next Article:BROKERED CERTIFICATE OF DEPOSIT RATES GENERALLY DECLINED IN LATEST PERIOD, SIA REPORTS


Related Articles
ANGEION RELEASES SECOND QUARTER FIGURES
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION REPORTS FISCAL 1993 RESULTS
ANGEION RECEIVES FDA AUTHORIZATION TO CONDUCT CLINICAL TRIALS
ST. JUDE MEDICAL ANNOUNCES FORMATION OF TACHYCARDIA BUSINESS UNIT
ST. JUDE MEDICAL DENIES CORDIS ACQUISITION SPECULATION AND AFFIRMS COMMITMENT TO DIVERSIFICATION STRATEGY
ANGEION REPORTS THIRD QUARTER RESULTS
ANGEION JOINS ST. JUDE PACESETTER SUIT AGAINST GUIDANT
ANGEION ICD IMPLANTED BY ST. JUDE/PACESETTER
Angeion Signs Cross-Licensing Agreement with St. Jude; Frees Angeion to Sign Distributors

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters